Should you buy Inovio Pharmaceuticals stock now?
No, the technical signal for Inovio Pharmaceuticals is currently Sell. Inovio Pharmaceuticals trades at $1.13 as of Oct 7, 2026. The technical analysis shows the following: MACD is negative (bearish trend) at -0.009 with falling momentum (signal: 0.006); RSI is at 43.9 (neutral zone); the stock is in a short-term downtrend (price below the 20-day average); the analyst price target of $3.17 points to 180.5% upside. This is a technical observation based on current data, not investment advice.
What is the price target for Inovio Pharmaceuticals stock?
The average analyst price target for Inovio Pharmaceuticals is $3.17. The current price is $1.13, which gives an upside of 180.5%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $2.85 and $3.49.
Is Inovio Pharmaceuticals a dividend stock?
No, Inovio Pharmaceuticals does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Inovio Pharmaceuticals stock?
Inovio Pharmaceuticals is rated as a stock in the risk category Extremely speculative. the annual standard deviation is 87.1%, which classifies the stock as Extremely speculative.
Is Inovio Pharmaceuticals overvalued?
No, Inovio Pharmaceuticals is considered undervalued based on the analyst price target (180.5% upside). Inovio Pharmaceuticals has the following valuation ratios: a P/S ratio of 961.5, a P/B ratio of 30.5. The analyst price target suggests that the stock is undervalued by 180.5%.
Is Inovio Pharmaceuticals overbought?
No, Inovio Pharmaceuticals is not overbought. RSI is at 43.9 (neutral zone). The technical indicators show: RSI is at 43.9 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 6.3% below the 20-day average (short-term downtrend). In addition, MACD is negative with falling momentum (bearish).
When is the next Inovio Pharmaceuticals earnings report?
Inovio Pharmaceuticals reports its next earnings on November 9, 2026. The stock currently trades at $1.13.
Is Inovio Pharmaceuticals shorted?
Yes, Inovio Pharmaceuticals is shorted with 21.4% of the free float sold short. This is an extremely high level of short selling, which points to great skepticism among institutional investors. The risk of a short squeeze on positive news or earnings is very high. The figure comes from our data provider EODHD, is reported about twice a month, and we check it every trading day.
Are insiders buying Inovio Pharmaceuticals stock?
No, insiders are not buying Inovio Pharmaceuticals shares – they are net sellers. Across the last 20 reported transactions, the split is 0 purchases and 20 sales, with a net 310,324 $ sold. Active sellers include Zoth Lota S., Weiner David B., David B Weiner and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Inovio Pharmaceuticals a good stock?
Based on our total score, Inovio Pharmaceuticals is rated as a disastrous stock with a total score of 6 out of 100. The stock scores very low on value, quality and momentum – it is among the worst in our database. The score is made up of Value: 2/100, Quality: 3/100, Momentum: 14/100. In addition: analysts see 180.5% upside to the price target; technical signal: Sell. Whether Inovio Pharmaceuticals is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Inovio Pharmaceuticals stock?
The outlook for Inovio Pharmaceuticals based on current data: the average analyst price target is $3.17 (+180.5%); the next earnings report is due on Nov 9, 2026, which can move the price. Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Inovio Pharmaceuticals stock falling?
Inovio Pharmaceuticals is falling right now. The technical indicators show: the price is 6.3% below the 20-day average; MACD is negative with falling momentum (bearish signal); short interest is 21.4% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis and insider section above.
How high can Inovio Pharmaceuticals go?
The average analyst price target for Inovio Pharmaceuticals is $3.17, which corresponds to a potential gain of 180.5% from the current price of $1.13. The stock has traded between $0.56 and $2.72 over the last 52 weeks. The price is 58.5% below the 52-week high, which can indicate potential if the underlying fundamentals are intact. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Inovio Pharmaceuticals fall?
The stock has traded as low as $0.56 over the last 52 weeks — that is 50.4% below the current price of $1.13. The biggest decline (drawdown) in the same period was 79.4% from high to low. Within a year, the price typically swings about ±87.1% (standard deviation — a measure of price swings). A difficult year could therefore mean a further decline of that size. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Inovio Pharmaceuticals do?
Inovio Pharmaceuticals develops DNA-based medicines. These are designed to treat diseases linked to HPV (a common virus), cancer, and infections. The company makes money by researching and selling these medicines, which it creates using its own method called SynCon technology.... The company belongs to the Healthcare sector, more specifically the Biotechnology industry, is headquartered in United States, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Inovio Pharmaceuticals as an investment.
Did Inovio Pharmaceuticals raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Inovio Pharmaceuticals. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history above.
Is Inovio Pharmaceuticals making money or losing money?
We have no current profitability data for Inovio Pharmaceuticals. See the latest report in the earnings history above.
Can Inovio Pharmaceuticals go bankrupt?
The bankruptcy risk of Inovio Pharmaceuticals is rated as elevated. Altman Z2 (a model for assessing financial distress) is -130.58 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. Debt relative to equity is 65% (moderate). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Inovio Pharmaceuticals have a lot of debt?
No, Inovio Pharmaceuticals has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 65%. For the healthcare sector, anything below 80% counts as low debt. In healthcare, 80-150% is typical — large pharma companies carry debt for research and acquisitions. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
